Alopecia Areata

Alopecia Areata

Trial

Trial ID: NCT06444451

Phase 2 | Injection | 36 week treatment period | 16 week safety follow up

• ≥ 18 years old
• Moderate to Severe Alopecia Areata (≥ 50% hair loss on head with a diagnosis duration of ≥ 6 months)
• Current episode of  hair loss is less than 8 years in duration
• No evidence of terminal hair regrowth within the past 6 months

Exclusion Criteria:

• Other forms of alopecia or any disease that requires topical treatment on the scalp
• Prior use of anti-OX40 therapies, Non-B-cell selective lymphocyte-depleting agents (e.g. alefacept, alemtuzumab), or JAK inhibitors for 12 months or longer

Alopecia Areata

Trial

Phase 3 | Oral tablet | 160 week treatment period | 30 day safety follow up

Trial ID: NCT06012240

• Between 12 and 64 years old
• Severe Alopecia Areata  (≥ 50% hair loss on head with no significant hair regrowth with past 3 months)
• Current episode of  hair loss is less than 8 years in duration
• No evidence of terminal hair regrowth within the past 6 months

Exclusion Criteria:

• Other forms of alopecia or any disease that requires topical treatment on the scalp
• Inadequate response to previous anti-JAK therapies
• A washout period is required for participants previously treated with biologic therapies, anti-JAKs, or other systemic treatments